



## PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

February 11, 2025

PRINCETON, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences. Management will also participate in one-on-one investor meetings.

### **Oppenheimer 35<sup>th</sup> Annual Healthcare Life Sciences Conference**

Date: Wednesday, February 12, 2025

Time: 12:40 PM EST

### **TD Cowen 45<sup>th</sup> Annual Health Care Conference**

Date: Tuesday, March 4, 2025

Time: 3:10 PM EST

A live audio webcast of the events will be available online at [Events & Presentations](#). An archived replay of the events will be available for 90 days following the webcast at [Events & Presentations](#).

### **About PMV Pharma**

PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. TP53 mutations are found in approximately half of all cancers. Our co-founder, Dr. Arnold Levine, established the field of p53 biology when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize more than four decades of p53 biology, PMV Pharma combines unique biological understanding with a pharmaceutical development focus. PMV Pharma is headquartered in Princeton, New Jersey. For more information, please visit [www.pmvpharma.com](http://www.pmvpharma.com).

### **Investors Contact:**

Tim Smith

Senior Vice President, Head of Corporate Development and Investor Relations

[investors@pmvpharma.com](mailto:investors@pmvpharma.com)

### **Media Contact:**

Kathy Vincent

Greig Communications

[kathy@greigcommunications.com](mailto:kathy@greigcommunications.com)